Vertex Pharmaceuticals Inc (VRTX)

107.29
0.72 0.67
NASDAQ : Health Care
Prev Close 108.01
Open 107.90
Day Low/High 106.52 / 109.73
52 Wk Low/High 75.90 / 143.45
Volume 3.02M
Avg Volume 1.64M
Exchange NASDAQ
Shares Outstanding 248.44M
Market Cap 22.28B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.

Vertex Pharmaceuticals Reaches Upside Price Target

Vertex Pharmaceuticals Reaches Upside Price Target

Base building pays off.

Dow Under Pressure, Nasdaq Rises on Gains in Amazon, Google

Dow Under Pressure, Nasdaq Rises on Gains in Amazon, Google

Stocks are mixed on Wednesday as financials retreat again while tech names move higher.

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.

Stock Futures Edge Higher as U.K. Invokes Article 50 in First Step of Brexit

Stock Futures Edge Higher as U.K. Invokes Article 50 in First Step of Brexit

Stock futures edge higher on Wednesday as markets await the United Kingdom taking the first step to formally remove itself from the European Union.

Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

Here are Wednesday's top research calls, including a downgrade of Twitter and new coverage of Facebook, Amazon and Alphabet.

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.

Why Concert Pharmaceuticals Is Music to Investors' Ears

Why Concert Pharmaceuticals Is Music to Investors' Ears

This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

What You Must Know About Cystic Fibrosis Drug CTP-656

What You Must Know About Cystic Fibrosis Drug CTP-656

Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.

Vertex To Acquire CTP-656 From Concert Pharmaceuticals For The Treatment Of Cystic Fibrosis

Vertex To Acquire CTP-656 From Concert Pharmaceuticals For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE).

Vertex To Present At The Cowen Healthcare Conference On March 6

Vertex To Present At The Cowen Healthcare Conference On March 6

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jana Partners are placing three members on Tiffany's board.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.

Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full-year and quarter-ended December 31, 2016.

Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex

Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising...

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.

Vertex Provides Update On Business And Financial Performance And Research And Development Programs

Vertex Provides Update On Business And Financial Performance And Research And Development Programs

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its business performance, including preliminary financial results for 2016 and a financial outlook for 2017, and an update on its ongoing...

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2016 Financial Results

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.